Vaccines against Clostridium difficile

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1466-1477

  Leuzzi, Rosanna ^a   Adamo, Roberto ^a   Scarselli, Maria ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

CDI; Clostridium difficile; Vaccine

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PEPTOCLOSTRIDIUM DIFFICILE; TRENDS;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; DRUG DISCOVERY; HUMANS;

EID: 84905868991     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28428     Document Type: Review

References (153)

1. Keessen EC, Gaastra W, Lipman LJ. Clostridium difficile infection in humans and animals, differences and similarities. Vet Microbiol 2011; 153:205-17; PMID:21530110; http://dx.doi.org/10.1016/j.vetmic.2011.03.020
2. al Saif N, Brazier JS. The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol 1996; 45:133-7; PMID:8683549; http://dx.doi.org/10.1099/00222615-45-2-133
3. Zidaric V, Beigot S, Lapajne S, Rupnik M. The occurrence and high diversity of Clostridium difficile genotypes in rivers. Anaerobe 2010; 16:371-5; PMID:20541023; http://dx.doi.org/10.1016/j.anaerobe.2010.06.001
4. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of anew pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935; 49:390-402; http://dx.doi.org/10.1001/archpedi.1935.01970020105010
5. Bartlett JGMN, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75:778-82; PMID:700321
6. Gerding DNMC, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S43-9; PMID:18177221; http://dx.doi.org/10.1086/521861
7. Vonberg RPKE, Kuijper EJ, Wilcox MH, Barbut F, Tüll P, Gastmeier P, van den Broek PJ, Colville A, Coignard B, Daha T, et al.; European C difficile-Infection Control Group; European Centre for Disease Prevention and Control (ECDC). Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14(Suppl 5):2-20; PMID:18412710; http://dx.doi.org/10.1111/j.1469-0691.2008.01992.x
8. Sorg JASA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190:2505-12; PMID:18245298; http://dx.doi.org/10.1128/JB.01765-07
9. Francis MB, Allen CA, Shrestha R, Sorg JA. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog 2013; 9:e1003356; PMID: 23675301; http://dx.doi.org/10. 1371/journal.ppat.1003356
10. Wheeldon LJWT, Worthington T, Lambert PA. Histidine acts as a co-germinant with glycine and taurocholate for Clostridium difficile spores. J Appl Microbiol 2011; (Forthcoming); PMID:21261795; http://dx.doi.org/10.1111/j. 1365-2672.2011.04953.x
11. Paredes-Sabja D, Sarker MR. Germination response of spores of the pathogenic bacterium Clostridium perfringens and Clostridium difficile to cultured human epithelial cells. Anaerobe 2011; 17:78-84; PMID:21315167; http://dx.doi.org/10.1016/j.anaerobe.2011.02.001
12. Sorg JASA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 2010; 192:4983-90; PMID:20675492; http://dx.doi.org/10.1128/JB. 00610-10
13. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47:241-59; PMID:16299351; http://dx.doi.org/10.1194/jlr.R500013-JLR200
14. Scaria J, Janvilisri T, Fubini S, Gleed RD, McDonough SP, Chang YF. Clostridium difficile transcriptome analysis using pig ligated loop model reveals modulation of pathways not modulated in vitro. J Infect Dis 2011; 203:1613-20; PMID: 21592991; http://dx.doi.org/10.1093/infdis/jir112
15. Janvilisri T, Scaria J, Chang YF. Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection. J Infect Dis 2010; 202:282-90; PMID:20521945; http://dx.doi.org/10.1086/653484
16. de la Riva L, Willing SE, Tate EW, Fairweather NF. Roles of cysteine proteases Cwp84 and Cwp13 in biogenesis of the cell wall of Clostridium difficile. J Bacteriol 2011; 193:3276-85; PMID:21531808; http://dx.doi.org/10. 1128/JB.00248-11
17. Kirby JM, Ahern H, Roberts AK, Kumar V, Freeman Z, Acharya KR, Shone CC. Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem 2009; 284:34666-73; PMID:19808679; http://dx.doi.org/10.1074/jbc.M109.051177
18. Janoir C, Péchiné S, Grosdidier C, Collignon A. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J Bacteriol 2007; 189:7174-80; PMID:17693508; http://dx.doi.org/10.1128/JB.00578-07
19. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18:247-63; PMID:15831824; http://dx.doi.org/10.1128/CMR.18.2.247-263.2005
20. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 2001; 69:1329-36; PMID:11179295; http://dx.doi.org/10.1128/IAI.69.3.1329-1336. 2001
21. Genth H, Dreger SC, Huelsenbeck J, Just I. Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int J Biochem Cell Biol 2008; 40:592-7; PMID:18289919; http://dx.doi.org/10.1016/j.biocel.2007.12.014
22. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 2012; 4:149-58; PMID:22237401; http://dx.doi.org/10.1159/000332946
23. Yamakawa K, Karasawa T, Ikoma S, Nakamura S. Enhancement of Clostridium difficile toxin production in biotin-limited conditions. J Med Microbiol 1996; 44:111-4; PMID:8642571; http://dx.doi.org/10.1099/00222615-44-2-111
24. Karlsson S, Burman LG, Akerlund T. Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology 2008; 154:3430-6; PMID:18957596; http://dx.doi.org/10.1099/mic.0.2008/019778-0
25. Karlsson S, Dupuy B, Mukherjee K, Norin E, Burman LG, Åkerlund T. Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infect Immun 2003; 71:1784-93; PMID:12654792; http://dx.doi.org/10.1128/IAI.71.4.1784-1793.2003
26. Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005; 49:3529-32; PMID:16048976; http://dx.doi.org/10.1128/AAC.49.8.3529-3532.2005
27. Drummond LJ, Smith DG, Poxton IR. Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile. J Med Microbiol 2003; 52:1033-8; PMID:14614060; http://dx.doi.org/10.1099/jmm.0.05387- 0
28. Gerber M, Walch C, Löffler B, Tischendorf K, Reischl U, Ackermann G. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol 2008; 57:776-83; PMID:18480337; http://dx.doi.org/10.1099/jmm.0. 47739-0
29. Aldape MJ, Packham AE, Nute DW, Bryant AE, Stevens DL. Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol 2013; 62:741-7; PMID:23429695; http://dx.doi.org/10. 1099/jmm.0.056218-0
30. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-7; PMID:10666429; http://dx.doi.org/10.1056/NEJM200002103420604
31. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93; PMID:11213096; http://dx.doi.org/10.1016/S0140-6736(00) 03592-3
32. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145:758-64; PMID:17116920; http://dx.doi.org/10.7326/0003-4819-145-10-200611210-00008
33. Geric B, Johnson S, Gerding DN, Grabnar M, Rupnik M. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol 2003; 41:5227-32; PMID:14605169; http://dx.doi.org/10.1128/JCM.41.11.5227-5232.2003
34. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307-12; PMID:10802189; http://dx.doi.org/10.1111/j.1574-6968.2000.tb09122.x
35. Gonçalves C, Decré D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42:1933-9; PMID:15131151; http://dx.doi.org/10.1128/JCM.42.5.1933-1939.2004
36. Martin H, Willey B, Low DE, Staempfli HR, McGeer A, Boerlin P, Mulvey M, Weese JS. Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol 2008; 46:2999-3004; PMID:18650360; http://dx.doi.org/10.1128/JCM.02437-07
37. Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. [table of contents.]. Microbiol Mol Biol Rev 2004; 68:373-402; PMID:15353562; http://dx.doi.org/10.1128/MMBR.68.3.373-402.2004
38. Papatheodorou P, Carette JE, Bell GW, Schwan C, Guttenberg G, Brummelkamp TR, Aktories K. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A 2011; 108:16422-7; PMID:21930894; http://dx.doi.org/10.1073/ pnas.1109772108
39. Aktories K, Schwan C, Papatheodorou P, Lang AE. Bidirectional attack on the actin cytoskeleton. Bacterial protein toxins causing polymerization or depolymerization of actin. Toxicon 2012; 60:572-81; PMID:22543189; http://dx.doi.org/10.1016/j.toxicon.2012.04.338
40. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009; 5:e1000626; PMID:19834554; http://dx.doi.org/10.1371/journal.ppat.1000626
41. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 2004; 53:887-94; PMID:15314196; http://dx.doi.org/10.1099/jmm.0.45610-0
42. Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011; 65:501-21; PMID:21682645; http://dx.doi.org/10.1146/annurev-micro-090110-102824
43. De Almeida MN, Heffernan H, Dervan A, Bakker S, Freeman JT, Bhally H, Taylor SL, Riley TV, Roberts SA. Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244. N Z Med J 2013; 126:9-14; PMID:24126745
44. Barbut F, Decré D, Lalande V, Burghoffer B, Noussair L, Gigandon A, Espinasse F, Raskine L, Robert J, Mangeol A, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actinspecific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54:181-5; PMID:15673514; http://dx.doi.org/10.1099/jmm.0.45804-0
45. Bacci S, Mølbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011; 17:976-82; PMID:21749757; http://dx.doi.org/10.3201/eid/1706.101483
46. McDonald LC, Killgore GE, Thompson A, Owens RC Jr., Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41; PMID:16322603; http://dx.doi.org/10. 1056/NEJMoa051590
47. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg 2013; 17:118-24, discussion 124-5; PMID:23086451; http://dx.doi.org/10.1007/s11605-012-2056-6
48. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-31; PMID:18507904; http://dx.doi.org/ 10.3201/eid1406.071447
49. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72; PMID:15337727; http://dx.doi.org/10.1503/cmaj.1041104
50. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60; PMID:16206099; http://dx.doi.org/10.1086/496986
51. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9; PMID:16322602; http://dx.doi.org/10.1056/NEJMoa051639
52. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73; PMID:21084111; http://dx.doi.org/10.1016/S0140-6736(10)61266-4
53. Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008; 13:18942; PMID:18761903
54. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12(Suppl 6):2-18; PMID:16965399; http://dx.doi.org/10.1111/j.1469-0691.2006.01580.x
55. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J Infect 2010; 61:1-8; PMID:20361997; http://dx.doi.org/10. 1016/j.jinf.2010.03.025
56. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol 2014; 30:54-62; PMID:24285002; http://dx.doi.org/10.1097/MOG.0000000000000018
57. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84; PMID:16182895; http://dx.doi.org/10.1016/S0140-6736(05)67420- X
58. Akerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, Burman LG. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008; 46:1530-3; PMID:18287318; http://dx.doi.org/10. 1128/JCM.01964-07
59. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38:646-8; PMID:14986247; http://dx.doi.org/10. 1086/382084
60. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, O'Connor L, Vaughan A, Crook DW, Wilcox MH, et al.; Infections in Oxfordshire Research Database. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55(Suppl 2):S77-87; PMID:22752869; http://dx.doi.org/10.1093/cid/cis356
61. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1):S12-8; PMID:18177217; http://dx.doi.org/10.1086/521863
62. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15:274-80; PMID:19825425; http://dx.doi.org/10.1016/j.anaerobe.2009.09.002
63. Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61:157-62; PMID:22398844
64. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58:403-10; PMID:19394704; http://dx.doi.org/10.1016/j.jinf.2009.03.010
65. Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-79; PMID:19929973; http://dx.doi.org/10.1111/j.1469-0691.2009.03099.x
66. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55; PMID:20307191; http://dx.doi.org/10. 1086/651706
67. Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt) 2011; 12:235-9; PMID:21767157; http://dx.doi.org/10.1089/sur.2010.080
68. Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55:351-7; PMID:22523271; http://dx.doi.org/10.1093/cid/ cis430
69. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31; PMID:21288078; http://dx.doi.org/10.1056/NEJMoa0910812
70. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr., Leney M, Sloan S, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205; PMID:20089970; http://dx.doi.org/10.1056/NEJMoa0907635
71. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64; PMID:16477549; http://dx.doi.org/10. 1086/501126
72. Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011; 52:1451-7; PMID:21628487; http://dx.doi.org/10.1093/cid/cir201
73. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75; PMID:12135033; http://dx.doi.org/10.1111/j.1572- 0241.2002.05839.x
74. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201-5; PMID:16319813
75. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107:89-95; PMID:22108454; http://dx.doi.org/10.1038/ajg.2011.398
76. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55(Suppl 2):S65-70; PMID:22752867; http://dx.doi.org/10.1093/cid/cis319
77. Shears P, Prtak L, Duckworth R. Hospital-based epidemiology: a strategy for 'dealing with Clostridium difficile'. J Hosp Infect 2010; 74:319-25; PMID:19726105; http://dx.doi.org/10.1016/j.jhin.2009.07.009
78. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55(Suppl 2):S88-92; PMID:22752870; http://dx.doi.org/10.1093/cid/cis335
79. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985; 47:349-52; PMID:3917975
80. Lima AA, Lyerly DM, Wilkins TD, Innes DJ, Guerrant RL. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 1988; 56:582-8; PMID:3343050
81. Mitchell TJ, Ketley JM, Haslam SC, Stephen J, Burdon DW, Candy DC, Daniel R. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut 1986; 27:78-85; PMID:3949240; http://dx.doi.org/10.1136/gut.27.1.78
82. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9; PMID:19252482; http://dx.doi.org/10.1038/nature07822
83. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28:965-9; PMID:19941990; http://dx.doi.org/10.1016/j.vaccine.2009.10.144
84. Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 2013; 207:323-30; PMID:23125448; http://dx.doi.org/10.1093/infdis/jis669
85. Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007; 11:5-10; PMID:16857405; http://dx.doi.org/10.1016/j.ijid.2006.04.003
86. Kuijper EJ, de Weerdt J, Kato H, Kato N, van Dam AP, van der Vorm ER, Weel J, van Rheenen C, Dankert J. Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis 2001; 20:528-34; PMID:11681431; http://dx.doi.org/10.1007/s100960100550
87. van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, Kuijper EJ. Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol 2004; 42:1035-41; PMID:15004050; http://dx.doi.org/10.1128/JCM.42.3.1035-1041. 2004
88. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467:711-3; PMID:20844489; http://dx.doi.org/10.1038/nature09397
89. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WD Jr. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999; 67:527-38; PMID:9916055
90. Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis 2012; 206:706-13; PMID:22732923; http://dx.doi.org/10.1093/infdis/ jis416
91. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr., Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988-95; PMID:11159994; http://dx.doi.org/10.1128/IAI.69.2.988- 995.2001
92. Tetanus vaccine. Wkly Epidemiol Rec 2006; 81:198-208; PMID:16710950
93. Diphtheria vaccine. Wkly Epidemiol Rec 2006; 81:24-32; PMID:16671240
94. Libby JM, Jortner BS, Wilkins TD. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun 1982; 36:822-9; PMID:7085078
95. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987; 55:2984-92; PMID:3679541
96. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995; 63:4619-27; PMID:7591115
97. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun 2007; 75:2826-32; PMID:17371854; http://dx.doi.org/10.1128/IAI.00127-07
98. Siddiqui F, O'Connor JR, Nagaro K, Cheknis A, Sambol SP, Vedantam G, Gerding DN, Johnson S. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. J Infect Dis 2012; 205:128-33; PMID:22124129; http://dx.doi.org/10.1093/infdis/jir688
99. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608-10; PMID:12595488; http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003
100. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-70; PMID:15765411; http://dx.doi.org/10.1053/j.gastro.2004.11.004
101. Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters. J Med Microbiol 2013; 62:1394-404; PMID:23518659; http://dx.doi.org/10.1099/jmm.0. 056796-0
102. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012; 30:2245-9; PMID:22306375; http://dx.doi.org/10.1016/j.vaccine.2012.01.065
103. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012; 30:4307-9; PMID:22682287; http://dx.doi.org/10.1016/j.vaccine.2012.01.056
104. Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013; 159:1254-66; PMID:23629868; http://dx.doi.org/10.1099/mic.0.066712-0
105. Nencioni L, Volpini G, Peppoloni S, Bugnoli M, De Magistris T, Marsili I, Rappuoli R. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun 1991; 59:625-30; PMID:1702767
106. Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996; 14:359-68; PMID:8735545; http://dx.doi.org/10.1016/ 0264-410X(95)00230-X
107. Lanis JM, Heinlen LD, James JA, Ballard JD. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 2013; 9:e1003523; PMID:23935501; http://dx.doi.org/10.1371/journal.ppat. 1003523
108. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 2007; 17:15R-22R; PMID:17237138; http://dx.doi.org/10.1093/glycob/cwm004
109. Lyerly DM. Vaccination against lethal Clostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A. Curr Microbiol 1990; 21:29-32; http://dx.doi.org/10.1007/BF02090096
110. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 1997; 65:2941-9; PMID:9199470
111. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 1999; 67:2145-52; PMID:10225867
112. Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun 1999; 67:5124-32; PMID:10496886
113. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 2011; 79:2295-302; PMID:21482682; http://dx.doi.org/10.1128/IAI.00130-11
114. Libby JM, Wilkins TD. Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun 1982; 35:374-6; PMID:6172384
115. Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, et al. Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun 2013; 81:2851-60; PMID:23716610; http://dx.doi.org/10.1128/IAI.01341-12
116. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012; 80:2678-88; PMID:22615245; http://dx.doi.org/10.1128/IAI.00215-12
117. Castagliuolo I, Sardina M, Brun P, DeRos C, Mastrotto C, Lovato L, Palù G. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect Immun 2004; 72:2827-36; PMID:15102793; http://dx.doi.org/10.1128/IAI.72.5.2827-2836.2004
118. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009; 27:3598-604; PMID:19464540; http://dx.doi.org/10.1016/j.vaccine.2009.03. 058
119. Seregin SS, Aldhamen YA, Rastall DP, Godbehere S, Amalfitano A. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 2012; 30:1492-501; PMID:22200503; http://dx.doi.org/10.1016/j. vaccine.2011.12.064
120. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012; 30:4249-58; PMID:22537987; http://dx.doi.org/10.1016/j.vaccine.2012.04.045
121. Ghose C, Verhagen JM, Chen X, Yu J, Huang Y, Chenesseau O, Kelly CP, Ho DD. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease. Infect Immun 2013; 81:2190-6; PMID:23545305; http://dx.doi.org/10.1128/IAI.01074-12
122. Yoshino Y, Kitazawa T, Ikeda M, Tatsuno K, Yanagimoto S, Okugawa S, Yotsuyanagi H, Ota Y. Clostridium difficile flagellin stimulates tolllike receptor 5, and toxin B promotes flagellin-induced chemokine production via TLR5. Life Sci 2013; 92:211-7; PMID:23261530; http://dx.doi.org/10.1016/j.lfs. 2012.11.017
123. Chaves-Olarte E, Weidmann M, Eichel-Streiber C, Thelestam M. Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest 1997; 100:1734-41; PMID:9312171; http://dx.doi.org/10.1172/JCI119698
124. Stabler RA, Dawson LF, Phua LT, Wren BW. Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J Med Microbiol 2008; 57:771-5; PMID:18480336; http://dx.doi.org/10. 1099/jmm.0.47743-0
125. Jin K, Wang S, Zhang C, Xiao Y, Lu S, Huang Z. Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum Vaccin Immunother 2013; 9:63-73; PMID:23143772; http://dx.doi.org/10.4161/hv.22434
126. Chumbler NM, Farrow MA, Lapierre LA, Franklin JL, Haslam DB, Goldenring JR, Lacy DB. Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog 2012; 8:e1003072; PMID:23236283; http://dx.doi.org/10.1371/journal.ppat.1003072
127. Farrow MA, Chumbler NM, Lapierre LA, Franklin JL, Rutherford SA, Goldenring JR, Lacy DB. Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex. Proceedings of the National Academy of Sciences of the United States of America 2013.
128. Péchiné S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol 2005; 43:5018-25; PMID:16207956; http://dx.doi.org/10.1128/JCM.43.10.5018-5025.2005
129. Péchiné S, Gleizes A, Janoir C, Gorges-Kergot R, Barc MC, Delmée M, Collignon A. Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol 2005; 54:193-6; PMID:15673516; http://dx.doi.org/10.1099/jmm.0.45800-0
130. Wright A, Drudy D, Kyne L, Brown K, Fairweather NF. Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol 2008; 57:750-6; PMID:18480333; http://dx.doi.org/10.1099/jmm.0.47532-0
131. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351:633-6; PMID:9500319; http://dx.doi.org/10.1016/ S0140-6736(97)08062-8
132. Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009; 33(Suppl 1):S24-8; PMID:19303565; http://dx.doi.org/10.1016/S0924- 8579(09)70012-3
133. Ní Eidhin DB, O'Brien JB, McCabe MS, Athié-Morales V, Kelleher DP. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 2008; 52:207-18; PMID:18093141; http://dx.doi.org/10.1111/j.1574-695X.2007.00363.x
134. Péchiné S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, Fattal E, Collignon A. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 2007; 25:3946-54; PMID:17433506; http://dx.doi.org/10.1016/j.vaccine.2007.02.055
135. Péchiné S, Denève C, Le Monnier A, Hoys S, Janoir C, Collignon A. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol Med Microbiol 2011; 63:73-81; PMID:21707776; http://dx.doi.org/10.1111/j.1574-695X.2011.00832.x
136. Sandolo C, Péchiné S, Le Monnier A, Hoys S, Janoir C, Coviello T, Alhaique F, Collignon A, Fattal E, Tsapis N. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. Eur J Pharm Biopharm 2011; 79:566-73; PMID:21664462; http://dx.doi.org/10.1016/j.ejpb. 2011.05.011
137. Berti F, Adamo R. Recent mechanistic insights on glycoconjugate vaccines and future perspectives. ACS Chem Biol 2013; 8:1653-63; PMID:23841819; http://dx.doi.org/10.1021/cb400423g
138. Monteiro MA, Ma Z, Bertolo L, Jiao Y, Arroyo L, Hodgins D, Mallozzi M, Vedantam G, Sagermann M, Sundsmo J, et al. Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines 2013; 12:421-31; PMID:23560922; http://dx.doi.org/10.1586/erv.13.9
139. Adamo R, Romano MR, Berti F, Leuzzi R, Tontini M, Danieli E, Cappelletti E, Cakici OS, Swennen E, Pinto V, et al. Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide. ACS Chem Biol 2012; 7:1420-8; PMID:22620974; http://dx.doi.org/10.1021/cb300221f
140. Reid CW, Vinogradov E, Li J, Jarrell HC, Logan SM, Brisson JR. Structural characterization of surface glycans from Clostridium difficile. Carbohydr Res 2012; 354:65-73; PMID:22560631; http://dx.doi.org/10.1016/j.carres.2012.02.002
141. Crossed D signapa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M, Minton NP, Serruto D, Unnikrishnan M. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol 2013; 195:545-55; PMID:23175653; http://dx.doi.org/10.1128/JB.01980-12
142. Oberli MA, Hecht ML, Bindschädler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 2011; 18:580-8; PMID:21609839; http://dx.doi.org/10.1016/j.chembiol.2011.03.009
143. Bertolo L, Boncheff AG, Ma Z, Chen YH, Wakeford T, Friendship RM, Rosseau J, Weese JS, Chu M, Mallozzi M, et al. Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile-ETEC conjugate vaccine. Carbohydr Res 2012; 354:79-86; PMID:22533919; http://dx.doi.org/10.1016/j.carres.2012.03.032
144. Ganeshapillai J, Vinogradov E, Rousseau J, Weese JS, Monteiro MA. Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr Res 2008; 343:703-10; PMID:18237724; http://dx.doi.org/10.1016/j.carres.2008.01.002
145. Martin CE, Broecker F, Oberli MA, Komor J, Mattner J, Anish C, Seeberger PH. Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope. J Am Chem Soc 2013; 135:9713-22; PMID:23795894; http://dx.doi.org/10. 1021/ja401410y
146. Jiao Y, Ma Z, Hodgins D, Pequegnat B, Bertolo L, Arroyo L, Monteiro MA. Clostridium difficile PSI polysaccharide: synthesis of pentasaccharide repeating block, conjugation to exotoxin B subunit, and detection of natural anti-PSI IgG antibodies in horse serum. Carbohydr Res 2013; 378:15-25; PMID:23597587; http://dx.doi.org/10.1016/j.carres.2013.03.018
147. Martin CE, Broecker F, Eller S, Oberli MA, Anish C, Pereira CL, Seeberger PH. Glycan arrays containing synthetic Clostridium difficile lipoteichoic acid oligomers as tools toward a carbohydrate vaccine. Chem Commun (Camb) 2013; 49:7159-61; PMID:23836132; http://dx.doi.org/10.1039/c3cc43545h
148. Cox AD, St Michael F, Aubry A, Cairns CM, Strong PC, Hayes AC, Logan SM. Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection. Glycoconj J 2013; 30:843-55; PMID:23974722; http://dx.doi.org/10.1007/s10719-013-9489-3
149. Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect 2012; 18(Suppl 5):100-8; PMID:22862783; http://dx.doi.org/10. 1111/j.1469-0691.2012.03944.x
150. Duerden BI. Contribution of a government target to controlling Clostridium difficile in the NHS in England. Anaerobe 2011; 17:175-9; PMID:21182972; http://dx.doi.org/10.1016/j.anaerobe.2010.12.004
151. Daneman N, Stukel TA, Ma X, Vermeulen M, Guttmann A. Reduction in Clostridium difficile infection rates after mandatory hospital public reporting: findings from a longitudinal cohort study in Canada. PLoS Med 2012; 9:e1001268; PMID:22815656; http://dx.doi.org/10.1371/journal.pmed.1001268
152. Hensgens MP, Keessen EC, Squire MM, Riley TV, Koene MG, de Boer E, Lipman LJ, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD). Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect 2012; 18:635-45; PMID:22536816; http://dx.doi.org/10.1111/j.1469-0691.2012.03853.x
153. Otten AM, Reid-Smith RJ, Fazil A, Weese JS. Disease transmission model for community-associated Clostridium difficile infection. Epidemiol Infect 2010; 138:907-14; PMID:20092667; http://dx.doi.org/10.1017/S0950268809991646